353 related articles for article (PubMed ID: 33222771)
1. Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles.
Lababidi N; Montefusco-Pereira CV; de Souza Carvalho-Wodarz C; Lehr CM; Schneider M
Eur J Pharm Biopharm; 2020 Dec; 157():200-210. PubMed ID: 33222771
[TBL] [Abstract][Full Text] [Related]
2. Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
Lababidi N; Ofosu Kissi E; Elgaher WAM; Sigal V; Haupenthal J; Schwarz BC; Hirsch AKH; Rades T; Schneider M
J Control Release; 2019 Nov; 314():62-71. PubMed ID: 31654686
[TBL] [Abstract][Full Text] [Related]
3.
Zhang L; Yang S; Wong LR; Xie H; Ho PC
Mol Pharm; 2020 Nov; 17(11):4256-4269. PubMed ID: 33084343
[TBL] [Abstract][Full Text] [Related]
4. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility.
Manniello MD; Del Gaudio P; Aquino RP; Russo P
Int J Pharm; 2017 Nov; 533(2):463-469. PubMed ID: 28377314
[TBL] [Abstract][Full Text] [Related]
5. Preparation and Characterization of Doripenem-Loaded Microparticles for Pulmonary Delivery.
Yildiz-Peköz A; Akbal O; Tekarslan SH; Sagirli AO; Mulazimoglu L; Morina D; Cevher E
J Aerosol Med Pulm Drug Deliv; 2018 Dec; 31(6):347-357. PubMed ID: 29877747
[No Abstract] [Full Text] [Related]
6. Development, Characterization, and In Vitro Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of Pseudomonas aeruginosa Biofilms.
Bahamondez-Canas TF; Ferrati S; Moraga-Espinoza DF; Smyth HDC
J Pharm Sci; 2018 Aug; 107(8):2172-2178. PubMed ID: 29698726
[TBL] [Abstract][Full Text] [Related]
7. Microparticles for inhalational delivery of antipseudomonal antibiotics.
Tsifansky MD; Yeo Y; Evgenov OV; Bellas E; Benjamin J; Kohane DS
AAPS J; 2008 Jun; 10(2):254-60. PubMed ID: 18454321
[TBL] [Abstract][Full Text] [Related]
8. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.
Yang Y; Tsifansky MD; Wu CJ; Yang HI; Schmidt G; Yeo Y
Pharm Res; 2010 Jan; 27(1):151-60. PubMed ID: 19847626
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
Wang J; Kutter JP; Mu H; Moodley A; Yang M
Int J Pharm; 2020 Nov; 590():119877. PubMed ID: 32927003
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
[TBL] [Abstract][Full Text] [Related]
11. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions.
Ernst J; Klinger-Strobel M; Arnold K; Thamm J; Hartung A; Pletz MW; Makarewicz O; Fischer D
Eur J Pharm Biopharm; 2018 Oct; 131():120-129. PubMed ID: 30063969
[TBL] [Abstract][Full Text] [Related]
12. Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication.
Wang J; Guo Y; Lu W; Liu X; Zhang J; Sun J; Chai G
Int J Pharm; 2024 Jun; 658():124208. PubMed ID: 38723731
[TBL] [Abstract][Full Text] [Related]
13. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
Yu H; Teo J; Chew JW; Hadinoto K
Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
[TBL] [Abstract][Full Text] [Related]
14. Poly(lactic-
Maghrebi S; Joyce P; Jambhrunkar M; Thomas N; Prestidge CA
ACS Appl Mater Interfaces; 2020 Feb; 12(7):8030-8039. PubMed ID: 32013379
[TBL] [Abstract][Full Text] [Related]
15. Oral nanotherapeutics with enhanced mucus penetration and ROS-responsive drug release capacities for delivery of curcumin to colitis tissues.
Huang Y; Canup BSB; Gou S; Chen N; Dai F; Xiao B; Li C
J Mater Chem B; 2021 Feb; 9(6):1604-1615. PubMed ID: 33471012
[TBL] [Abstract][Full Text] [Related]
16. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers.
Ungaro F; d'Angelo I; Coletta C; d'Emmanuele di Villa Bianca R; Sorrentino R; Perfetto B; Tufano MA; Miro A; La Rotonda MI; Quaglia F
J Control Release; 2012 Jan; 157(1):149-59. PubMed ID: 21864595
[TBL] [Abstract][Full Text] [Related]
17. Improved effect of amikacin-loaded poly(D,L-lactide-co-glycolide) nanoparticles against planktonic and biofilm cells of Pseudomonas aeruginosa.
Sabaeifard P; Abdi-Ali A; Gamazo C; Irache JM; Soudi MR
J Med Microbiol; 2017 Mar; 66(2):137-148. PubMed ID: 28260589
[TBL] [Abstract][Full Text] [Related]
18. Antiviral activity against Zika virus of a new formulation of curcumin in poly lactic-co-glycolic acid nanoparticles.
Pacho MN; Pugni EN; Díaz Sierra JB; Morell ML; Sepúlveda CS; Damonte EB; García CC; D'Accorso NB
J Pharm Pharmacol; 2021 Mar; 73(3):357-365. PubMed ID: 33793877
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis.
Alhajj N; Yahya MFZR; O'Reilly NJ; Cathcart H
Eur J Pharm Sci; 2024 Jan; 192():106654. PubMed ID: 38013123
[TBL] [Abstract][Full Text] [Related]
20. Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
Craparo EF; Porsio B; Schillaci D; Cusimano MG; Spigolon D; Giammona G; Cavallaro G
Nanomedicine (Lond); 2017 Jan; 12(1):25-42. PubMed ID: 27879162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
